A nurse is reinforcing teaching with a client who asks which diagnostic test is the preferred method for detecting cervical cancer. Which is an appropriate response by the nurse?

Choice A rationale Transvaginal ultrasound is a diagnostic imaging tool used to visualize the uterus, ovaries, and fallopian tubes. While it is excellent for detecting structural abnormalities, ovarian cysts, or endometrial thickening, it is not the preferred or standard screening method for cervical cancer. It cannot identify the cellular changes or dysplasia on the cervix that characterize early-stage malignancy. It is often used as a follow-up tool if other symptoms are present, but it lacks the specificity for cervical screening. Choice B rationale An endometrial biopsy involves taking a tissue sample from the lining of the uterus to check for uterine or endometrial cancer. This procedure is specifically targeted at the interior of the uterine cavity and does not evaluate the cells of the cervix. It is typically performed when a client has abnormal uterine bleeding. Since cervical cancer and endometrial cancer are distinct diseases occurring in different anatomical locations, this biopsy is not the correct test for screening or detecting cervical malignancy. Choice C rationale CA 125 is a protein found in the blood that acts as a tumor marker. Elevated levels of CA 125 are most commonly associated with ovarian cancer, although levels can also rise due to endometriosis or pelvic inflammatory disease. It is not a specific or reliable screening tool for cervical cancer. Using blood markers for cervical cancer screening is inappropriate because they lack the sensitivity and specificity provided by direct cellular examination of the cervical tissue during a routine pelvic exam. Choice D rationale The Papanicolaou test, commonly known as a Pap smear, is the preferred and primary screening method for the early detection of cervical cancer and precancerous lesions. During this test, cells are scraped from the cervix and examined under a microscope for abnormalities. It has significantly reduced cervical cancer mortality by identifying cellular changes before they become invasive. This test specifically targets the transformation zone of the cervix, making it the most effective tool for routine cervical health monitoring.